FEB 23, 2015 10:09 AM PST

FDA Greenlights First Direct-to-Consumer Genetic Carrier Test for Bloom Syndrome

WRITTEN BY: Judy O'Rourke
The FDA has approved the Bloom Syndrome carrier test from 23andMe, Mountain View, Calif, a direct-to-consumer (DTC) genetic test to determine whether a healthy person has a variant in a gene that could lead to their children inheriting the serious disorder.

The agency is also classifying carrier screening tests as class II, and intends to exempt these devices from FDA premarket review, which creates the least burdensome regulatory path for autosomal recessive carrier screening tests with similar uses to enter the market.

"The FDA believes that in many circumstances it is not necessary for consumers to go through a licensed practitioner to have direct access to their personal genetic information. Today's authorization and accompanying classification, along with FDA's intent to exempt these devices from FDA premarket review, supports innovation and will ultimately benefit consumers," says Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health.

In general, carrier testing is a type of genetic testing performed on people who display no symptoms for a genetic disorder but may be at risk for passing it on to their children. A carrier for a genetic disorder has inherited one normal and one abnormal allele for a gene associated with the disorder. A child must inherit two abnormal alleles, one copy from each parent, in order for symptoms to appear.

No test is perfect. Given the probability of erroneous results and the rarity of these mutations, professional societies typically recommend that only prospective parents with a family history of a genetic disorder undergo carrier screening. For example, when a gene mutation is expected to be very rare, a positive result for the mutation may have a high probability of being wrong.

Like other home-use tests for medical purposes, the FDA requires the results to be conveyed in a way that consumers can understand and use. This is the same approach the FDA has taken with other over-the-counter consumer products such as pregnancy, cholesterol, and HIV tests for home use.

While the FDA is not limiting who should or should not use these tests, it is requiring that the company explain to the consumer in the product labeling what the results might mean for prospective parents interested in seeing if they carry a genetic disorder.

If sold over the counter, the FDA is also requiring 23andMe to provide information to consumers about how to obtain access to a board-certified clinical molecular geneticist or equivalent to assist in pre- and post-test counseling.

The test is intended only for postnatal carrier screening in adults of reproductive age, and the results should be used in conjunction with other available laboratory and clinical information for any medical purposes.

23andMe previously marketed a Personal Genome Service in the United States, but it ceased providing direct health information to US consumers after the FDA issued a 2013 Warning Letter. The letter directed the company to stop selling the product because of failure to obtain marketing clearance or approval to assure their tests were accurate, reliable, and clinically meaningful.

[Source: FDA]
About the Author
  • Judy O'Rourke worked as a newspaper reporter before becoming chief editor of Clinical Lab Products magazine. As a freelance writer today, she is interested in finding the story behind the latest developments in medicine and science, and in learning what lies ahead.
You May Also Like
MAY 25, 2021
Genetics & Genomics
Mitochondrial Dysfunction May Raise Schizophrenia Risk in 22q Patients
MAY 25, 2021
Mitochondrial Dysfunction May Raise Schizophrenia Risk in 22q Patients
A disorder called 22q11.2 deletion syndrome (22q) affects about one in 2,000 births, and causes dysfunction in every org ...
MAY 26, 2021
Plants & Animals
Sterilizing Mosquitos with CRISPR to Control Disease
MAY 26, 2021
Sterilizing Mosquitos with CRISPR to Control Disease
By knocking out a gene in male mosquitos' testes, researchers demonstrate a powerful population control technique.
JUN 06, 2021
Genetics & Genomics
How Autism-Associated Mutations in One Gene Impact the Brain
JUN 06, 2021
How Autism-Associated Mutations in One Gene Impact the Brain
Autism spectrum disorder is complex; it presents differently in different patients and may be influenced by many factors ...
JUN 16, 2021
Microbiology
DNA - It's What's for Dinner (For Some Bacteria)
JUN 16, 2021
DNA - It's What's for Dinner (For Some Bacteria)
There may be a trillion species of microbes on the planet, so clearly there's still a lot we don't know about these micr ...
JUL 20, 2021
Cell & Molecular Biology
Do Phages Drive Bacterial Evolution?
JUL 20, 2021
Do Phages Drive Bacterial Evolution?
Antibiotics are a standard treatment for bacterial infections, but more and more of these bacterial infections can't be ...
JUL 23, 2021
Neuroscience
Researchers Switch Fear Response 'On' and 'Off' in Mice
JUL 23, 2021
Researchers Switch Fear Response 'On' and 'Off' in Mice
The fear response can be switched 'on' and 'off' in mice by targeting certain cells in the brain with pu ...
Loading Comments...